Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | REGN7508 (ROXI-VTE-II) | Phase 3 | Ongoing | intravenous | #ERROR: Missing required arguments value for function GPT_CLASSIFY. | |
| Regeneron Pharmaceuticals Inc. | REGN9933 - (ROXI-VTE-I) | Venous thromboembolism (VTE) | Phase 3 | Trial Planned | intravenous | Anticoagulant |
| Regeneron Pharmaceuticals Inc. | Pozelimab + Cemdisiran - (ACCESS-1) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Data Released | Subcutaneous | Hematology |
| Regeneron Pharmaceuticals Inc. | Pozelimab + cemdisiran | Geographic atrophy | Phase 3 | Trial Planned | Subcutaneous | Opthalmic |
| Regeneron Pharmaceuticals Inc. | Itepekimab - (AERIFY) | Chronic obstructive pulmonary disease (COPD) | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Regeneron Pharmaceuticals Inc. | Linvoseltamab | Heavily Pre-treated Multiple Myeloma | Phase 3 | Ongoing | Intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | Trevogrumab, semaglutide with and without garetosmab - (COURAGE) | Obesity | Phase 2 | Data Released | Subcutaneous injection | Endocrinology |
| Regeneron Pharmaceuticals Inc. | Tirzepatide and mibavademab | Obesity | Phase 2 | Ongoing | Subcutaneous | Endocrinology |
